Worth $3 BILLIONS buyout for that reason alone....see ya there ! I can wait...no problem I'm sitting on 60,000 shares !
Jail time next...hope they like orange suits and having a girlfriend named Bubba.
I know some p eople who went to LeHigh. They were losers who couldn't get in the real universities. In the Philly area you got U of Penn , Princeton, Drexel, Penn State and much better places to go.
SA Bill Mauer's write up was based on cash at hand nothing more. He assigned no value, whatsoever, to Provenge or the pipeline they have. No value whatsoever to a takeout. The guy is just a blatant short. He got called out on it too.
They are having discussions about what the price would be. IN order to get what they are asking they are cutting COGS to pretty things up as that will support the justification for buyout terms... Yes, JNJ, Novartis, Merck, others will be very interested.
He's really advising shorting at $3 really crazy !!!! There are already 60 MM shares short.
And when the weak longs have finally sold, that seems to me to be the best buy signal of all. However that does not change the facts for OS.
More like $20. 6 ph 2 and ph 3 candidates, higher sales.
Break even used to be $400 million. Now that $125 M in costs has been reduced, that means its more like $275 million. Do the math, $275 million divided by $93k per treatment, is 2956 or around 3,000 patients per year. Significantly less than 20k patients ! See the upside once this catches on the upside is amazing. 240,000 new cases a year are prognosed so if we h it 10 % of those with provenge, its more like 24000 * 93000 = $2.2 Billion is potential.
WOuldnt surprise me at all. During the CC yesterday they even said "we are considering all strategic options." And they did not deny or confirm buyout, just said no comment which is wall street way of saying yes. $20 is the price. Mark it. FDA and EU seals it.
Agreed. Provenge and immunotherapy in general is a paradigm shift in cancer treatment. There are very powerful vested interests who want to maintaint he status quo of chemo. In time DNDN will be blockbuster . Mark it.